The December 1st implementation date for the new USP General Chapter <797> has been postponed. The current chapter (last revised 2008) will continue to remain in effect until further notice.
Did you know our New Fellows Program offers botanist led pollen walks for Allergy Fellows? In late July, Sam Wauford, Eastern Regional Sales Manager and botanist, along with Matthew Brennan, Account Executive for NJ/NY/CT, conducted a pollen walk for eight Allergy Fellows in training from Montifiore Medical Center, Bronx, NY. Finding weeds in the urban…
One year ago, we announced that our company had become the sole provider of venom immunotherapy products in the U.S.—a position brought about by the departure from the market of the only other supplier. In the ensuing year, we have committed all of our resources to ensuring a long-term, consistent supply of venom products for our customers. We’re pleased to share with you this brief overview of what we’ve been working on, and advances CMS has made with reimbursements.
Read as letter Read related AAAAI/ACAAI email to members At the end of February 2018, we learned that we will be the only supplier of venom immunotherapy products in North America. In light of this situation, we have evaluated our production capabilities as they relate to our ability to indefinitely supply the entire North American…
Joint Message Announcing Venom Extract Shortage Task Force Report The AAAAI and ACAAI previously announced a venom extract shortage due to ALK – Abello A/S experiencing a manufacturing delay in regards to its venom products. In response, we formed a task force of experts to generate guidance outlining recommendations for our members which could lead…
WARNING Important Safety Information
(See full prescribing information for complete boxed warning.)
Intended for use only by licensed health care provider experienced in administering allergenic extracts and trained to provide immediate emergency treatment in the event of a life-threatening reaction. Observe patients for at least 30 minutes following administration. Immunotherapy may not be suitable for patients with medical conditions that reduce their ability to withstand a systemic reaction. Allergenic extracts can cause serious systemic reactions, including anaphylactic shock and in rare cases death, especially in patients who have severe or steroid-dependent asthma, cardiovascular disease, or in patients who use beta blockers. Do not inject intravenously. This product is intended for subcutaneous injection for immunotherapy and percutaneous use for diagnosis. Refer to contraindications, warnings, precautions, adverse reaction and over dosage for more detailed information.